MedImmune and Abpro team on Ang2-VEGF targeting antibody

By Gareth Macdonald contact

- Last updated on GMT

AstrzaZeneca’s MedImmune has set up a spin-out company with Abpro that will develop a bi-specific antibody therapeutic.

The joint venture – AbMed - will focus on an antibody that targets angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF).

The firm will develop the molecule for a number of undisclosed therapeutic areas. 

AbMed – which will operate as a subsidiary of Abpro – will hold development and commercialization rights to the programme, while MedImmune will receive development, regulatory and sales milestones and royalties.

An Abpro Spokesman told us the firm "will be leveraging its DiversImmune platform to bring the antibody to clinical trials. Abpro has an extensive network of manufacturing partners to prepare for clinical trials. We are committed to our partners in the US to carry this out​."

He added that: "Once our clinical trials are completed, we will make this therapy widely available to treat patients and improve their quality of life​."

This was echoed by Rebecca Einhorn from MedImmune who told us "AbPro will have day-to-day leadership in overseeing the new company, AbMed, and AbPro’s core technology platform, DiversImmune, will be used to further refine the antibody​."

She declined to disclose the therapeutic areas that AbMed will focus on.

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more